

JUN. 18. 2004 2:12PM AVENTIS US PAT DEPT  
TO: US USPTO GENERAL

NO. 4347 RECEIVED  
COMM-FAX FAX DEPT

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
USST98048 US DIV 1

Applicants:  
STUTZMANN, et al.

Serial No.  
10/644,109

Filing Date:  
August 20, 2003

Title of Invention:  
NOVEL THERAPEUTIC USE OF LOW MOLECULAR WEIGHT HEPARINS

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at 703-872-9306, on

Date of Deposit June 18, 2004

Printed Name of Person Signing Certificate Phyllis Renee McGinnis

Signature *Phyllis Renee McGinnis*

Total Number of Pages Sent: 53

Attorney: Raymond S. PARKER, III

Group Art Unit: 1623

Examiner: Ganapathy, KRISHNAN

TO: Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Amendment, 37 CFR §1.115   | <input type="checkbox"/> Fee Transmittal                                |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____                    |
| <input checked="" type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>Copies of 5 references</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____                                    |
| <input type="checkbox"/> Maintenance Fee Transmittal           |   |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

JUN. 18. 2004 2:12PM

AVENTIS US PAT DEPT

NO. 4347

P. 3

RECEIVED  
COMM. FOR PAT. & TRADEMARKS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
STUTZMANN, et al.

Examiner: Ganapathy, KRISHNAN

Art Unit: 1623

Application No.: 10/644,109

Filed: August 20, 2003

Title: NOVEL THERAPEUTIC USE OF LOW  
MOLECULAR WEIGHT HEPARINS

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on 703-872-9306

Date of Transmission

June 18, 2004  
Phyllis Renee McGinnis  
Signature

**AMENDMENT AND RESPONSE PURSUANT TO 37 C.F.R. §1.115**

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This paper is in response to the Office Action mailed December 18, 2003, regarding pending claims 1-19. Applicants also file concurrently herewith a Petition under 37 C.F.R. §1.136(a) to extend the time for response for three (3) months, or until June 18, 2004.